Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus. It is grouped under the following drug class(es): DNA polymerase inhibitors, Nucleotides and Reverse Transcriptase Inhibitors. Its therapeutic use is listed as anti-infectives. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Besivo and PMCDG dipivoxil. Its PubChem CID is 6480442.
Besifovir dipivoxil
| CAS No | 441785-26-8 |
|---|---|
| Molecular Formula | C22H34N5O8P |
| Molecular Weight | 527.5 g/mol |
| Synonyms | [[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA.
The listed CAS number is 441785-26-8.
The listed molecular formula is C22H34N5O8P.
The listed molecular weight is 527.5 g/mol.
[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate.
The source lists Besivo and PMCDG dipivoxil.